Statistical Methodology, Novartis Pharma AG, Basel, Switzerland.
Stat Med. 2010 May 10;29(10):1096-106. doi: 10.1002/sim.3845.
The goal of a clinical Phase II dose finding study is to describe the dose response relationship and to find a target dose (TD) or dose range that ensures a certain efficacy. In many applications, however, it is useful to consider combinations of dose and time under treatment instead of the dose only. The estimation of a minimum effective dose as a function of time allows, e.g. for a decision on an optimal initial treatment duration, if this initial treatment is followed by a maintenance therapy or aftercare which is supposed to start when a certain response rate is achieved. Bretz et al. (Biometrics 2005; 61:738-748) proposed a methodology that combines formal hypothesis testing for dose response with flexible modeling of the dose response relationship and estimating a target dose. In this paper a framework is proposed that allows for an extension of this methodology to a procedure that takes into account both, dose and time under treatment based on repeated binary data. A set of nonlinear mixed effects models is considered. The primary goal of such a study is the estimation of a minimum effective dose defined by the marginal probability, either in absolute terms or relative to placebo, as a function of time.Examples for the TD as a function of time are given under specific model assumptions using a response function which depends on a cumulated dose response over time. The proposed models are illustrated by a case study on the treatment of psoriasis. The precision of the TD estimation as given by its standard error and bias are presented under different dose-response models and scenarios. The precision conditioned on the correct underlying model shape is contrasted with the precision of a procedure that incorporates a model selection step after which the TD is estimated using the selected model, and with the precision obtained under a misspecified model.
临床二期剂量探索研究的目标是描述剂量反应关系,并找到一个目标剂量(TD)或剂量范围,以确保一定的疗效。然而,在许多应用中,考虑治疗下的剂量和时间组合而不是仅考虑剂量是很有用的。作为时间函数的最小有效剂量的估计,例如可以用于决定最佳的初始治疗持续时间,如果初始治疗后是维持治疗或后续护理,而维持治疗或后续护理应该在达到一定的反应率时开始。Bretz 等人(Biometrics 2005;61:738-748)提出了一种方法,将剂量反应的正式假设检验与剂量反应关系的灵活建模和目标剂量估计相结合。本文提出了一个框架,允许将这种方法扩展到一种考虑基于重复二分类数据的治疗下剂量和时间的程序。考虑了一组非线性混合效应模型。这种研究的主要目标是估计最小有效剂量,该剂量由边际概率定义,无论是绝对的还是相对于安慰剂,作为时间的函数。在特定的模型假设下,使用随时间累积的剂量反应的响应函数,给出了 TD 作为时间函数的示例。提出的模型通过一个关于治疗银屑病的案例研究来说明。在不同的剂量反应模型和场景下,给出了 TD 估计的精度,即其标准误差和偏差。在正确的基础模型形状下的精度与纳入模型选择步骤后使用所选模型估计 TD 的程序的精度进行了对比,并与在指定模型下获得的精度进行了对比。